**Specification Table**TableSubject areaBiologyMore specific subject areaBreast CancerType of dataTable, FigureHow data was acquiredMicroarray analysis; data were done by Phalanx Biotech Group using Human OneArray (array version HOA 6.1) which contains 31,741 mRNA probes that can detect 20, 672 genes in human genome.Data formatAnalyzedExperimental factorsBoth MCF-7 and MDA-MB-231cells (\~500×10^3^ cells) were treated with DS (2.30 µM) for three days followed by RNA extraction and analysis.Experimental featuresMCF-7 and MDA-MB-231 cells were cultured in phenol red free DMEM-F12 (1:1) medium supplemented with 10% dextran charcoal treated fetal bovine serum, 50 U/mL penicillin and 50 µg/mL streptomycin as Pen-Strep and 2 mM of [l]{.smallcaps}-glutamine at 37 °C in a humidified atmosphere of 95% air and 5% CO~2~. The cells (\~500×10^3^ cells) were allowed to attach in the 25 cm^3^ culture flasks in 6 mL volume and after 24 h the cultures were treated with DS (2. 30 µM) for three days.Data source locationN/AData accessibilityData is within this article and available at the NCBI database via GEO series accession numbers GEO: GSE79465; GEO: GPL 19137; GEO:GSM2095708; GEO:GSM2095709; GEO:GSM2095710

**Value of the data**•May stimulate further research on the utility of DS as a preventive agent of metastatic breast cancer.•May facilitate new therapies to target specific genes that are associated with metastatic breast cancer.•Genes participating in MAPK signaling pathways are the probable targets of breast cancer metastasis.

1. Data {#s0005}
=======

[Table 1](#t0005){ref-type="table"} showed data on the global gene expression profile in MCF-7 and MDA-MB-231 cell lines treated with vehicle (DMSO) or DS in vitro. [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"} showed gene ontology analysis based on molecular functions ([Table 2](#t0010){ref-type="table"}), biological processes ([Table 3](#t0015){ref-type="table"}), and cellular components ([Table 4](#t0020){ref-type="table"}). Various canonical pathways, which were significantly altered between the cell lines (vehicle-treated) or after DS treatment, were presented in [Table 5](#t0025){ref-type="table"}. The genes that were overlapped between these two cell lines (MCF-7 and MDA-MB-231) after DS treatment were listed in [Table 6](#t0030){ref-type="table"} and in a Venn diagram format in [Fig. 1](#f0005){ref-type="fig"}.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Cell culture, DS treatment, and extraction of nucleic acids {#s0015}
----------------------------------------------------------------

The detailed procedure of cell culture, treatment with DS, and the isolation of RNA have been described in our previous study [@bib1]. In brief, human breast adenocarcinoma, MCF-7 (ER^+^) and MDA-MB-231 (ER^−^) cells were maintained in phenol red free DMEM-F12 (1:1) medium supplemented with 10% dextran charcoal treated fetal bovine serum, 50 U/mL penicillin and 50 µg/mL streptomycin and 2 mM of [l]{.smallcaps}-glutamine. The cells (\~500×10^3^ cells) were allowed to attach in the 25 cm^3^ culture flasks in 6 mL volume for 24 h before treating with DS (2.30 µM) for three days. After complete removal of the media, the cells were trypsinized, resuspended in the medium, and washed twice with PBS. RNA extraction was made by Trizol reagent as described previously [@bib1]. Briefly, Trizol reagent (Invitrogen, Carlsberg, CA) was used to lyse the cells. Chloroform was added to the lysate for phase separation. The clean aqueous phase (RNA) was transferred to a clean 1.5 ml Eppendorf tube and RNA was precipitated by 2-propanol. After a quick wash in 75% ethanol, the extracted RNA was dissolved in nuclease-free water. The samples (extracted RNA) were further treated with DNase I (Promega, Madison, WI), to remove DNA contamination, if any. Finally, the concentration of RNA was determined by NanoDrop 2000c (Thermo Fisher Scientific, Waltham, MA) and the samples were stored at −80 °C until sending to Phalanx Biotech Group for microarray analysis.

2.2. Microarray analysis {#s0020}
------------------------

Microarray analysis was carried out by Phalanx Biotech Group using OneArray (array version HOA 6.1) which contains 31,741 mRNA probes that can detect 20, 672 genes in human genome. In brief, the purity of the extracted RNA was checked using NanoDrop ND-1000. The Pass criteria for absorbance ratios are established as A260/A280≥1.8 and A260/A230≥1.5. RIN values are ascertained using Agilent RNA 6000 Nano assay to determine RNA integrity. Pass criteria for RIN value is established at \>6. Genomic DNA (gDNA) contamination was evaluated by gel electrophoresis. Any RNA that did not meet these criteria was excluded from the analysis.

Target preparation was performed using an Eberwine-based amplification method with Amino Allyl MessageAmp II aRNA Amplification Kit (Ambion, AM1753) to generate amino-allyl antisense RNA (aa-aRNA). Labeled aRNA coupled with NHS-CyDye (Cy5) was prepared and purified prior to hybridization. Purified coupled aRNA was quantified using NanoDrop ND-1000; pass criteria for CyDye incorporation efficiency at \>15 dye molecular/1000 nt. All the raw data are available in NCBI׳s gene expression Omnibus and are accessible through GEO series accession number GSE79465 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79465>).

2.3. Gene expression data analysis {#s0025}
----------------------------------

Global scaling normalization (scatter plot, histogram and volcano plot, principal component analysis) was carried out, and the fold changes (cut-off (log2 \|fold change\|≧1)) were calculated based on the relative signal intensities (scanned by Agilent 0.1 XDR protocol). A filtering step was performed using Rosetta error model [@bib2] which allowed for determination of the statistical significance of every pair wise gene between different groups. The default multiple testing corrections used was Benjamini and Hochberg [@bib3] false discovery rate with a *q* value cutoff \<0.05. The testing correction was the least stringent of all corrections and provided a good balance between the discovery of statistically significant genes and the limitation of false positive occurrences by removing all gene spots with a *q* value \>0.05 in all conditions. This procedure narrowed the list of genes to those significantly affected by DS treatment. Gene annotation was based on two data bases: NCBI ref seq release 57.ensembl release 70 cDNA sequences and homo_sapiens_core_70_37. Finally the pathway enrichment analysis (PEA) was utilized to group and display genes with similar expression profiles. The online tool Database for Annotation, Visualization, and Integrated Discovery (DAVID) [@bib4] was used for PEA. The selected KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways with an adjusted EASE (Expression Analysis Systematic Explore) score *p* value ≤0.05 and count \>2. Data gained by this technique may help to understand more on in vitro studies of botanical natural products used in breast cancer treatment. The pathway analysis was used to examine functional correlations within the cell lines and different treatment groups. Data sets containing gene identifiers and corresponding expression values were uploaded into the application. Each gene identifier was mapped to its corresponding gene object in the KEGG pathway map with an adjusted EASE (Expression Analysis Systematic Explore) score *p* value ≤0.05 and count \>2. Networks were "named" on the most common functional group(s) present in the database. Canonical pathway analysis (GeneGo maps) as evaluated acknowledged function-specific genes significantly present within the network [@bib5].

Appendix A. Transparency document {#s0035}
=================================

Supplementary material

This study was partially supported by the United States Department of Agriculture Research Specific Cooperative agreement No. 58-6408-1-603-04.

Transparency document associated with this article can be found in the online version at [http://dx.doi.org/10.1016/j.dib.2016.05.040](http://doi:10.1016/j.dib.2016.05.040){#ir0010}.

![Venn diagram of the overlap among DEGs of MCF-7 and MDA-MB-231 cells exposed to DS (2.30 µM, 72 h). The MCF-7 and MDA-MB-231 cells shared seven genes of which six genes were found in the data base.](gr1){#f0005}

###### 

Number of differentially expressed genes in MCF-7 and MDA-MB-231 cells.

Table 1

      Comparison                Up-regulated (number)   Down-regulated (number)
  --- ------------------------- ----------------------- -------------------------
  1   MCF-7C/MDA-MB-231C        2439                    2002
  2   MCF-7C/MCF-7T             395                     406
  3   MDA-MB-231C/MDA-MB-231T   36                      60
  4   MCF-7T/MDA-MB-231T        1700                    1926

###### 

Gene ontology analysis based on molecular functions.

Table 2

  Gene set name                     Number of genes in the gene set   Number of genes overlap                                                                                                       
  --------------------------------- --------------------------------- ----------------------------------------- ---------------------------------------- ------------------------------------------ -----
  Magnesium ion binding             452                               38[⁎](#tbl2fnStar){ref-type="table-fn"}   --                                       125[⁎](#tbl2fnStar){ref-type="table-fn"}   97
  Cytokine activity                 195                               --                                        8[⁎](#tbl2fnStar){ref-type="table-fn"}   --                                         --
  Enzyme binding                    523                               38                                        --                                       141[⁎](#tbl2fnStar){ref-type="table-fn"}   109
  Actin binding                     326                               23                                        --                                       95[⁎](#tbl2fnStar){ref-type="table-fn"}    76
  Cytoskeletal protein binding      504                               --                                        --                                       135[⁎](#tbl2fnStar){ref-type="table-fn"}   102
  Purine ribonucleotide binding     1836                              95                                        --                                       410[⁎](#tbl2fnStar){ref-type="table-fn"}   306
  Ribonucleotide binding            1836                              95                                        --                                       410[⁎](#tbl2fnStar){ref-type="table-fn"}   --
  Purine nucleotide binding         1918                              96                                        --                                       424[⁎](#tbl2fnStar){ref-type="table-fn"}   323
  Nucleotide binding                2245                              110                                       --                                       485[⁎](#tbl2fnStar){ref-type="table-fn"}   --
  Adenyl ribonucleotide binding     1497                              81                                        --                                       332[⁎](#tbl2fnStar){ref-type="table-fn"}   --
  ATP binding                       1477                              81                                                                                 328[⁎](#tbl2fnStar){ref-type="table-fn"}   251
  Protein domain specific binding   331                               --                                        --                                       89[⁎](#tbl2fnStar){ref-type="table-fn"}    --
  Nucleoside binding                1612                              84                                        --                                       353[⁎](#tbl2fnStar){ref-type="table-fn"}   278
  Purine nucleoside binding         1601                              83                                        --                                       350[⁎](#tbl2fnStar){ref-type="table-fn"}   273
  Adenyl nucleotide binding         1577                              82                                        --                                       345[⁎](#tbl2fnStar){ref-type="table-fn"}   270
  Transcription factor binding      513                               29                                        --                                       127[⁎](#tbl2fnStar){ref-type="table-fn"}   --
  Enzyme activator activity         335                               21                                        --                                       88[⁎](#tbl2fnStar){ref-type="table-fn"}    62

The asterisk indicates *q*\<0.05 [@bib3].

###### 

Gene ontology analysis based on biological process.

Table 3

  Gene set name                                                              Number of genes in the gene set   Number of genes in overlap                                                                                                     
  -------------------------------------------------------------------------- --------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------ ------------------------------------------
  Protein complex biogenesis                                                 505                               47[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        129[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Protein complex assembly                                                   505                               47[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        129[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Macromolecular complex assembly                                            665                               55[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        --                                         --
  Macromolecular complex subunit organization                                710                               56[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        165                                        --
  Protein oligomerization                                                    174                               20[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        50                                         --
  Protein amino acid phosphorylation                                         667                               47[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        156                                        --
  Protein heterooligomerization                                              52                                10[⁎](#tbl3fnStar){ref-type="table-fn"}   --                                        17                                         --
  Negative regulation of cell proliferation                                  361                               22                                        10[⁎](#tbl3fnStar){ref-type="table-fn"}   81                                         86[⁎](#tbl3fnStar){ref-type="table-fn"}
  Cell cycle                                                                 776                               46                                        --                                        210[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Regulation of cell death                                                   815                               52                                        11                                        205[⁎](#tbl3fnStar){ref-type="table-fn"}   165[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of apoptosis                                                    804                               52                                        11                                        202[⁎](#tbl3fnStar){ref-type="table-fn"}   163[⁎](#tbl3fnStar){ref-type="table-fn"}
  Induction of programmed cell death                                         321                               21                                        --                                        94[⁎](#tbl3fnStar){ref-type="table-fn"}    73[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of programmed cell death                                        812                               52                                        11                                        202[⁎](#tbl3fnStar){ref-type="table-fn"}   163[⁎](#tbl3fnStar){ref-type="table-fn"}
  Induction of apoptosis                                                     320                               21                                        --                                        93[⁎](#tbl3fnStar){ref-type="table-fn"}    72[⁎](#tbl3fnStar){ref-type="table-fn"}
  Positive regulation of cell death                                          435                               27                                        --                                        119[⁎](#tbl3fnStar){ref-type="table-fn"}   95[⁎](#tbl3fnStar){ref-type="table-fn"}
  Cell cycle process                                                         565                               34                                        --                                        147[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Regulation of binding                                                      153                               78                                        4                                         52[⁎](#tbl3fnStar){ref-type="table-fn"}    42[⁎](#tbl3fnStar){ref-type="table-fn"}
  Positive regulation of Programmed cell death                               433                               27                                        --                                        117[⁎](#tbl3fnStar){ref-type="table-fn"}   94[⁎](#tbl3fnStar){ref-type="table-fn"}
  Positive regulation of apoptosis                                           430                               27                                        --                                        116[⁎](#tbl3fnStar){ref-type="table-fn"}   93[⁎](#tbl3fnStar){ref-type="table-fn"}
  Cell death                                                                 719                               47                                        8                                         176[⁎](#tbl3fnStar){ref-type="table-fn"}   146[⁎](#tbl3fnStar){ref-type="table-fn"}
  Mitotic cell cycle                                                         370                               --                                        --                                        100[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Cell division                                                              295                               --                                        --                                        83[⁎](#tbl3fnStar){ref-type="table-fn"}    --
  Death                                                                      724                               47                                        8                                         176[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Programmed cell death                                                      611                               40                                        8                                         152[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Apoptosis                                                                  602                               38                                        8                                         150[⁎](#tbl3fnStar){ref-type="table-fn"}   --
  Regulation of DNA binding                                                  121                               --                                        4                                         41[⁎](#tbl3fnStar){ref-type="table-fn"}    35[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of cell proliferation                                           787                               48                                        12                                        182                                        183[⁎](#tbl3fnStar){ref-type="table-fn"}
  Positive regulation of cell proliferation                                  414                               29                                        --                                        --                                         97[⁎](#tbl3fnStar){ref-type="table-fn"}
  Cell proliferation                                                         436                               28                                        --                                        110                                        99[⁎](#tbl3fnStar){ref-type="table-fn"}
  Neuron differentiation                                                     438                               --                                        --                                        --                                         98[⁎](#tbl3fnStar){ref-type="table-fn"}
  Death                                                                      724                               47                                        8                                         --                                         146[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of locomotion                                                   192                               15                                        --                                        56                                         50[⁎](#tbl3fnStar){ref-type="table-fn"}
  Cell migration                                                             276                               --                                        5                                         69                                         66[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of cell motion                                                  193                               16                                        --                                        56                                         50[⁎](#tbl3fnStar){ref-type="table-fn"}
  Blood vessel development                                                   245                               --                                        --                                        64                                         60[⁎](#tbl3fnStar){ref-type="table-fn"}
  Neuron projection development                                              256                               --                                        --                                        --                                         62[⁎](#tbl3fnStar){ref-type="table-fn"}
  Vasculature development                                                    251                               --                                        --                                        64                                         61[⁎](#tbl3fnStar){ref-type="table-fn"}
  Cell projection organization                                               368                               --                                        --                                        91                                         82[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of cellular component size                                      271                               --                                        6                                         66                                         64[⁎](#tbl3fnStar){ref-type="table-fn"}
  Transmembrane receptor protein serine/threonine kinase signaling pathway   103                               12                                        --                                        35                                         31[⁎](#tbl3fnStar){ref-type="table-fn"}
  Regulation of cell migration                                               169                               14                                        --                                        51                                         44[⁎](#tbl3fnStar){ref-type="table-fn"}
  Hemopoietic or lymphoid organ development                                  260                               --                                        --                                        60                                         61[⁎](#tbl3fnStar){ref-type="table-fn"}
  Positive regulation of developmental process                               278                               18                                        6                                         72                                         64[⁎](#tbl3fnStar){ref-type="table-fn"}
  Axon guidance                                                              107                               --                                        --                                        --                                         31[⁎](#tbl3fnStar){ref-type="table-fn"}
  Hemopoiesis                                                                236                               --                                        --                                        --                                         56[⁎](#tbl3fnStar){ref-type="table-fn"}
  Positive regulation of locomotion                                          98                                12                                        --                                        32                                         29[⁎](#tbl3fnStar){ref-type="table-fn"}
  Locomotory behavior                                                        274                               --                                                                                  --                                         63[⁎](#tbl3fnStar){ref-type="table-fn"}
  Response to vitamin                                                        66                                --                                                                                  --                                         22[⁎](#tbl3fnStar){ref-type="table-fn"}

The asterisk indicates *q*\<0.05 [@bib3].

###### 

Gene ontology analysis based on cellular component.

Table 4

  Gene set name                                  Number of genes in the gene set   Number of genes in overlap                                                                                                      
  ---------------------------------------------- --------------------------------- ------------------------------------------ ----------------------------------------- ------------------------------------------ ------------------------------------------
  Membrane-enclosed Lumen                        1856                              111[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                        397[⁎](#tbl4fnStar){ref-type="table-fn"}   --
  Organelle lumen                                1820                              108[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                        391[⁎](#tbl4fnStar){ref-type="table-fn"}   300
  Intracellular organelle Lumen                  1779                              106[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                        382[⁎](#tbl4fnStar){ref-type="table-fn"}   291
  Nuclear lumen                                  1450                              91[⁎](#tbl4fnStar){ref-type="table-fn"}    --                                        312[⁎](#tbl4fnStar){ref-type="table-fn"}   243
  Nucleoplasm                                    882                               62[⁎](#tbl4fnStar){ref-type="table-fn"}    --                                        186                                        --
  Intracellular Non-membrane-bounded Organelle   2596                              134[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                        --                                         --
  Non-membrane-bounded Organelle                 2596                              134[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                        --                                         --
  Cytosol                                        1330                              74[⁎](#tbl4fnStar){ref-type="table-fn"}    --                                        285[⁎](#tbl4fnStar){ref-type="table-fn"}   --
  Cytoskeleton                                   1381                              74[⁎](#tbl4fnStar){ref-type="table-fn"}    --                                        --                                         --
  Nuclear matrix                                 56                                9[⁎](#tbl4fnStar){ref-type="table-fn"}     --                                        --                                         --
  Nuclear periphery                              61                                9[⁎](#tbl4fnStar){ref-type="table-fn"}     --                                        --                                         --
  Extracellular space                            685                               --                                         12[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                         
  Extracellular region part                      960                               --                                         14[⁎](#tbl4fnStar){ref-type="table-fn"}   --                                         --
  Lytic vacuole                                  211                               17                                         --                                        71[⁎](#tbl4fnStar){ref-type="table-fn"}    56[⁎](#tbl4fnStar){ref-type="table-fn"}
  Lysosome                                       211                               --                                         --                                        71[⁎](#tbl4fnStar){ref-type="table-fn"}    56[⁎](#tbl4fnStar){ref-type="table-fn"}
  Vacuole                                        252                               18                                         --                                        79[⁎](#tbl4fnStar){ref-type="table-fn"}    62[⁎](#tbl4fnStar){ref-type="table-fn"}
  Basolateral plasma Membrane                    203                               14                                         --                                        64⁎                                        --
  Non-membrane-bounded Organelle                 2596                              134                                        --                                        543[⁎](#tbl4fnStar){ref-type="table-fn"}   --
  Intracellular Non-membrane-bounded Organelle   2596                              134                                        --                                        543[⁎](#tbl4fnStar){ref-type="table-fn"}   413[⁎](#tbl4fnStar){ref-type="table-fn"}
  Anchoring junction                             172                               14                                         --                                        52[⁎](#tbl4fnStar){ref-type="table-fn"}    46[⁎](#tbl4fnStar){ref-type="table-fn"}
  Adherens junction                              155                               --                                         --                                        48[⁎](#tbl4fnStar){ref-type="table-fn"}    41[⁎](#tbl4fnStar){ref-type="table-fn"}
  Golgi apparatus                                872                               --                                         --                                        197[⁎](#tbl4fnStar){ref-type="table-fn"}   150
  Mitochondrion                                  1087                              56                                         --                                        239[⁎](#tbl4fnStar){ref-type="table-fn"}   --
  Cell fraction                                  1083                              --                                         --                                        237[⁎](#tbl4fnStar){ref-type="table-fn"}   209[⁎](#tbl4fnStar){ref-type="table-fn"}
  Nucleolus                                      698                               --                                         --                                        107[⁎](#tbl4fnStar){ref-type="table-fn"}   129
  Cell leading edge                              138                               --                                         --                                        41[⁎](#tbl4fnStar){ref-type="table-fn"}    37[⁎](#tbl4fnStar){ref-type="table-fn"}
  Extracellular matrix                           345                               --                                         5                                         --                                         78[⁎](#tbl4fnStar){ref-type="table-fn"}
  Insoluble fraction                             839                               --                                         --                                        --                                         159[⁎](#tbl4fnStar){ref-type="table-fn"}

The asterisk indicates *q*\<0.05 [@bib3].

###### 

Gene set enrichment analysis based on the canonical pathway.

Table 5

  Gene set name                      Number of genes in the gene set   Number of genes in overlap                                                                                      
  ---------------------------------- --------------------------------- ---------------------------- ---------------------------------------- ----------------------------------------- -----------------------------------------
  MAPK signaling pathway             267                               --                           7[⁎](#tbl5fnStar){ref-type="table-fn"}   70                                        56
  Pathways in cancer                 328                               27                           --                                       99[⁎](#tbl5fnStar){ref-type="table-fn"}   76[⁎](#tbl5fnStar){ref-type="table-fn"}
  Apoptosis                          87                                --                           --                                       34[⁎](#tbl5fnStar){ref-type="table-fn"}   23
  Lysosome                           117                               --                           --                                       41[⁎](#tbl5fnStar){ref-type="table-fn"}   37[⁎](#tbl5fnStar){ref-type="table-fn"}
  VEGF signaling pathway             75                                --                           --                                       29[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Focal adhesion                     201                               --                           --                                       60[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Prostate cancer                    89                                --                           --                                       32[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  mTOR signaling pathway             52                                --                           --                                       21[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Pancreatic cancer                  72                                --                           --                                       26[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Colorectal cancer                  84                                --                           --                                       29[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Renal cell carcinoma               70                                --                           --                                       25[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Regulation of actin cytoskeleton   215                               16                           --                                       59[⁎](#tbl5fnStar){ref-type="table-fn"}   --
  Small cell lung cancer             84                                --                           --                                       28[⁎](#tbl5fnStar){ref-type="table-fn"}   --

The asterisk indicates *q*\<0.05 [@bib3].

###### 

List of genes overlapped between the two cell lines.

Table 6

  Gene symbol   Description of the gene                                Log2 (ratio)                   
  ------------- ------------------------------------------------------ -------------- ------- ------- -------
  ERRFI1        ERBB receptor feedback inhibitor 1                     0.01           1.33    1.06    −0.35
  MMP1          Matrix metallopeptidase 1 (interstitial collagenase)   1.59           2.70    2.09    0.96
  SOD2          Superoxide dismutase 2, mitochondrial                  2.54           1.04    1.08    2.61
  IL24          Interleukin 24                                         −0.93          1.44    2.86    0.37
  PTRF          Polymerase I and transcript release factor             −1.54          −2.35   −1.03   −0.23
  ALKBH5        AlkB, alkylation repair homolog 5 (*E. coli*)          −0.70          −1.36   −1.01   −0.40
